Q2 2013 Company News
Expansion of Biomarker Analysis Services
Q2 2013 – Last month, we announced the appointment of Doinita Serban, Ph.D. as our new Director of Biomarker Research and the installation of a Luminex 200 System which will be used to perform multiplex assays. Doinita’s extensive experience with biomarker assay development, validation, and profiling of disease panels, coupled with the implementation of the Luminex platform, has enabled us to broaden our biomarker analysis capabilities to now include additional assay formats, such as multiplex biomarker assays, gene expression and profiling assays.
Read the announcement.
Presentation on in vitro Drug Metabolism Studies to Support IND Submissions
In May, our Director of DMPK, David Johnson, Ph.D., was invited to present at the BIOCOM seminar entitled Virtual Drug Development in Southern California: A Pre-Clinical Focus. David, and representatives from two other Southern California contract research organizations, presented pertinent information regarding the types of research that should be conducted during the discovery and pre-clinical phases of drug development programs. Dr. Johnson’s presentation focused on the in vitro DMPK assays that are needed to help make critical decisions to support IND-submissions.
View the presentation (PDF).
AAPS National Biotechnology Conference
In May, our lead Pharmacokineticist, Ahmed Kousba, M.D., Ph.D., presented two posters on pharmacokinetics at the AAPS National Biotechnology Conference. PDFs of these posters are available on our website using the links below:
- Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-peptide, in Patients with Type 1 Diabetes Mellitus (PDF)
- Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats (PDF)
MicroConstants’ Biomarker Research Department provides biomarker analysis services to support preclinical and clinical diagnostic research of new therapeutics, including target validation, high-throughput screening (HTS), lead discovery, and validation of clinical endpoints. We perform biomarker assay development, validation, and profiling of disease panels using a variety of assay formats, including Luminex, LC/MS/MS, ELISA, gene expression and profiling assays.